Navigation Links
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)

BARCELONA, Spain, November 5 /PRNewswire/ -- SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC).

SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the time of resubmission. SALVAT believes that the response submitted today to the FDA fully addresses the Agency request.

The Approvable Letter did not raise any questions related to efficacy or safety of CETRAXAL(R) Otic Solution.

SALVAT is currently evaluating potential commercial partners in the United States to licensing out CETRAXAL(R) and expects to launch it during the second quarter of 2009, subject to FDA approval.

The NDA for CETRAXAL(R) seeks marketing approval for the treatment of Acute Otitis Externa in pediatric (aged 1 year and older) and adult patients.


CETRAXAL(R) is a Ciprofloxacin 0.2% Otic Solution for the treatment of Acute Otitis Externa. In a phase III clinical trial compared to Neomycin, Polymyxin B sulfates and Hydrocortisone otic solution (NPH), CETRAXAL(R) obtained a clinical cure rate of 93.9% in pediatric patients (vs. 76.0% in the NPH group) and resolved or improved otalgia in 99.2% of the patients. There were no adverse reactions with an incidence higher than 1%. CETRAXAL(R) will be available in sterile, preservative-free single-dose containers which make easy to ensure correct dosing and to place drops into the ear.


SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced NCE is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments and by emphasizing collaborations regarding its pipeline products.


Cristina Viayna,

Business Development & Licensing, ,

Phone: +1-305-774-9727.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
2. Telik Announces Financial Results for 2008 Third Quarter
3. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
4. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
5. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
6. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
7. Misonix Announces New Distribution Agreement for The Netherlands
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Post Your Comments:
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Biology News(10 mins):